All In Biotech

Drug Trial Radar · NCT07281105

EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study

A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Clinical Trial of EG-501 for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Aug 23, 2018

Primary completion

Aug 12, 2025

Study completion Aug 12, 2025

Sponsor

Lead sponsor
Evergreen Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Vanderbilt University Medical Center
First posted
Dec 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neuropsychiatric systemic lupus erythematosus with cognitive impairment (NPSLE-CI) is a serious, disabling, and potentially life-threatening manifestation of SLE, affecting up to 80% of patients with cognitive impairments ("brain fog"), leading to substantial disability, approximately 2 times higher unemployment risk, reduced health-related quality of life (HRQoL), and mortality 2-14 times higher than the general population (standardized mortality ratio, SMR). No approved therapies exist for NPSLE cognitive dysfunction, representing a high-priority unmet need for this FDA-recognized serious condition with major functional and psychosocial burden. The objective of this study is to evaluate the safety, tolerability and efficacy of EG-501 in a precise patient subset with NPSLE. Participants will complete a full 14-week clinical trial, receiving either EG-501 or a placebo.

Conditions

  • Neuropsychiatric Systemic Lupus Erythematosus
  • Systemic Lupus Erythematosus (SLE)
  • Cognitive Impairment

Interventions

  • PlaceboDrug

    The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (EG-501).

  • EG-501Drug

    EG-501/ EG-MNTP-01 is an oral, low-affinity NMDA receptor antagonist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Repeatable Battery for Assessment of Neuropsychological Status (RBANS) Total Index Score at endpoint (Visit 4)Time frame: 12 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic

    Cleveland, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • UT Health Houston

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.